Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis (SAFESYNC NG)
2026年9月3日 更新者:Braile Biomedica Ind. Com. e Repr. Ltda.
Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study
The objective of this pivotal, prospective, multicenter, single-arm clinical trial is to evaluate the safety and clinical performance of the Next-Generation INOVARE® SAFESYNC Bioprosthetic Heart Valve, implanted via a transcatheter approach, in patients with severe aortic stenosis, an indication for TAVI, and intermediate or higher surgical risk.
The study will enroll 40 participants.
調査の概要
状態
まだ募集していません
研究の種類
介入
入学 (推定)
40
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Clinical Research Department - Braile Biomédica
- 電話番号:+5517 21367000
- メール:pesquisa@braile.com.br
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Severe aortic valve stenosis diagnosed according to criteria established in current guidelines.
- Intermediate or higher surgical risk, defined as a Society of Thoracic Surgeons (STS) score ≥4%.
- Indication for transcatheter aortic valve implantation (TAVI).
- Willing and able to participate in the study and provide written informed consent.
Exclusion Criteria:
- Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., indication for a mechanical heart valve).
- Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, nitinol (titanium or nickel), or contrast media that cannot be adequately managed with premedication. This includes heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITTS).
- Blood dyscrasias, including leukopenia (white blood cell count <1,000/mm³), thrombocytopenia (platelet count <100,000 cells/mm³), history of coagulopathy, or hypercoagulable states.
- Active infection, including endocarditis.
- Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or requirement for mechanical hemodynamic support.
- Stroke or transient ischemic attack (TIA) within 2 months prior to the index procedure.
- History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy.
- Estimated life expectancy of less than 24 months.
- Other medical, social, or psychological conditions that, in the investigator's opinion, may prevent the participant from providing informed consent or adequately complying with the study protocol.
- Pre-existing prosthetic heart valve, either biological or mechanical, in the aortic position.
- Concomitant severe mitral or tricuspid valve disease.
- Hypertrophic obstructive cardiomyopathy.
- Successful percutaneous coronary intervention (PCI) performed within 48 hours prior to TAVI.
- Femoral artery diameter <5.5 mm for SAFESYNC 20-24 mm, <6.0 mm for SAFESYNC 26-28 mm, or <6.5 mm for SAFESYNC 30 mm.
- High risk of aortic annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract.
- High risk of coronary obstruction, defined by computed tomography angiography as coronary ostial height <10 mm with narrow sinuses of Valsalva (SOV), with a mean SOV diameter <3 mm greater than the bioprosthetic valve size.
- Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%.
- Severe chronic kidney disease, defined as glomerular filtration rate (GFR) <30 mL/min/1.73 m².
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:INOVARE® SAFESYNC Next-Generation TAVI
|
Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Device Success According to VARC-3 Criteria
時間枠:30 days after the procedure
|
Technical success; Absence of mortality; Absence of surgery or intervention related to the device or to major vascular, access-related, or cardiac structural complications; Intended valve performance, defined as mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation.
|
30 days after the procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Technical Success According to VARC-3 Criteria
時間枠:During the procedure
|
Defined as freedom from mortality; successful vascular access, delivery of the device, and retrieval of the delivery system; correct positioning of a single prosthetic heart valve in the intended anatomical location; and freedom from surgery or intervention related to the device or to a major vascular, access-related, or cardiac structural complication.
Results will be reported as the number and percentage of participants achieving technical success.
|
During the procedure
|
|
Incidence and Severity of Paravalvular Leak
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
Paravalvular leak will be assessed by transthoracic echocardiography and classified according to severity.
The number and percentage of participants with paravalvular leak in each severity category will be reported.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Mean Transvalvular Aortic Pressure Gradient Assessed
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
Mean transvalvular aortic pressure gradient will be assessed by transthoracic echocardiography and reported in mmHg.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Distribution of Participants by New York Heart Association Functional Class
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
Functional status will be assessed using the New York Heart Association (NYHA) Functional Classification.
The classification ranges from Class I to Class IV, where Class I represents no limitation of physical activity and Class IV represents inability to perform physical activity without symptoms and/or symptoms at rest.
Higher NYHA classes indicate worse functional status.
Results will be reported as the number and percentage of participants in each NYHA functional class.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of New Permanent Pacemaker Implantation
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
New permanent pacemaker implantation following the index transcatheter aortic valve implantation procedure will be assessed.
Results will be reported as the number and percentage of participants who undergo new permanent pacemaker implantation.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of All-Cause Mortality
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
All-cause mortality will be assessed throughout follow-up.
Results will be reported as the number and percentage of participants who die from any cause.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Stroke
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
Stroke events will be assessed based on clinical neurological evaluation and classified according to Valve Academic Research Consortium 3 (VARC-3) definitions.
Results will be reported as the number and percentage of participants experiencing stroke.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve-Related Reintervention
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve-related reintervention will be defined as any surgical or transcatheter intervention performed to treat dysfunction or failure of the implanted study valve.
Results will be reported as the number and percentage of participants undergoing valve-related reintervention.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Dysfunction According to VARC-3 Definitions
時間枠:30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve dysfunction will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions.
Bioprosthetic valve dysfunction includes structural valve deterioration, non-structural valve dysfunction, valve thrombosis, and endocarditis.
Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve dysfunction and according to the corresponding category.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Failure According to VARC-3 Definitions
時間枠:30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
Bioprosthetic valve failure will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions.
Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve failure.
|
30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年11月1日
一次修了 (推定)
2027年7月1日
研究の完了 (推定)
2032年6月1日
試験登録日
最初に提出
2026年8月19日
QC基準を満たした最初の提出物
2026年9月3日
最初の投稿 (実際)
2026年9月8日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月8日
QC基準を満たした最後の更新が送信されました
2026年9月3日
最終確認日
2026年9月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- SAFESYNC NG
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。